{"id":564731,"date":"2021-09-21T10:40:02","date_gmt":"2021-09-21T10:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=564731"},"modified":"2021-09-21T10:40:02","modified_gmt":"2021-09-21T10:40:02","slug":"prostate-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/prostate-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_564731.html","title":{"rendered":"Prostate Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1632203220.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Prostate Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1632203220.png\" alt=\"Prostate Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cProstate Cancer &#8211; Pipeline Insight, 2021,\u201d report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;Prostate Cancer Pipeline Insight&rdquo;<\/a><\/strong> report provides comprehensive insights about key companies and pipeline drugs in the Prostate Cancer pipeline landscapes.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report comprises <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Prostate Cancer pipeline<\/a><\/strong> drug profiles, including clinical and non-clinical stage products. It also includes the Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prostate Cancer pipeline products.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/5706ff1ccf506f9141fc112c4d1eb956.jpg\" alt=\"\" \/>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Prostate Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rdmost prevalent type of cancer in the US and the fourth most common worldwide.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways from the Prostate Cancer Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as AstraZeneca\/Merck Sharp &amp; Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research &amp; Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer\/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, Merck Sharp &amp; Dohme, etc., are developing therapies for the treatment of Prostate Cancer.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emerging therapies such as Lynparza, Opdivo, Lutathera, Relugolix, Niraparib, HC-1119, Ipatasertib, Talazoparib, Rucaparib, ProstAtak, Keytruda, are expected to have a significant impact on the Prostate Cancer market in the coming years.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get an overview of pipeline landscape <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Prostate Cancer Clinical Trials Analysis&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Prostate Cancer Pipeline Therapies along with Key Players:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lynparza :AstraZeneca\/Merck Sharp &amp; Dohme&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Opdivo: Bristol-Myers Squibb&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lutathera: Novartis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Relugolix: Myovant Sciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Niraparib: Janssen Research &amp; Development&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HC-1119: Hinova Pharmaceuticals USA<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ipatasertib: Hoffmann-La Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Talazoparib: Pfizer\/Astellas Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rucaparib: Clovis Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ProstAtak: Advantagene or Candel Therapeutics&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Keytruda: Merck Sharp &amp; Dohme<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of Prostate Cancer Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major Players: AstraZeneca\/Merck Sharp &amp; Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research &amp; Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer\/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, Merck Sharp &amp; Dohme, and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pipeline Therapies: Lynparza, Opdivo, Lutathera, Relugolix, Niraparib, HC-1119, Ipatasertib, Talazoparib, Rucaparib, ProstAtak, Keytruda, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>1<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>2<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>3<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Overview<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>4<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer- Analytical Perspective In-depth Commercial Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>5<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Pipeline Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>6<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Late Stage Products (Phase II\/III)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>7<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Mid Stage Products (Phase II)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>8<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Early Stage Products (Phase I)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>9<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Preclinical Stage Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>10<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Therapeutics Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>11<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Inactive Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>12<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Company-University Collaborations (Licensing\/Partnering) Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>13<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Key Companies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>14<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Key Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>15<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>16&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Market Drivers and Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>17<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Future Perspectives and Conclusion<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>18<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prostate Cancer Analyst Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>19<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>20<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get a customized pipeline report <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Prostate Cancer Drugs Pipeline Report<\/a><\/strong>&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=prostate-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=prostate-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cProstate Cancer &#8211; Pipeline Insight, 2021,\u201d report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/prostate-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_564731.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-564731","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=564731"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564731\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=564731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=564731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=564731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}